Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - -...
May 08, 2024 06:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and...
May 06, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...
April 22, 2024 16:30 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will...
April 16, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint...
March 26, 2024 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment...
March 13, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment...
February 28, 2024 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash...
February 26, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint...
February 21, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...